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The remaining hurdle to the
creation of babies specifically to
save the life of an ailing brother
or sister was removed in Britain
last month by the fertility
regulatory body to the delight of
afflicted families and alarm of
those who fear the advent of a
‘designer’ baby age.
The decision of the UK’s
Human Fertilisation and
Embryology Authority gives new
hope to the parents of a two-
year-old boy with a potentially
fatal blood disorder who want to
select a baby who will be a
tissue match for their son.
But doctors and regulators
insisted that strict controls and
decisions taken on a case-by-
case basis will continue to
prevent the selection of babies
for their hair or eye colour or their
intelligence, should that ever
become possible. The boy,
Joshua Fletcher, from Northern
Ireland, suffers from Diamond
Blackfan anaemia, which can
only be cured by a bone marrow
transplant. His parents have not
been able to find a tissue match.
They asked the HFEA for
permission to have their
embryos, to be created in a
fertility lab, tested in the hope of
finding a sibling who can be a
donor. The baby’s umbilical cord
blood would be used for a
transplant.
The full 18-member HFEA
decided in a landmark decision
to change the rules so that
tissue-matching tests could be
carried out on embryos even
though they are not directly in
the interest of the future baby,
but would only benefit the sick
sibling. The authority concluded
that research had shown the
tests, although invasive, did no
harm to the embryo and were
acceptable if they might save a
child’s life.
Fertility doctors lined up to
welcome the decision. “The
often-used term ‘designer baby’
is misleading here — we are not
talking about engineering a child
to have a certain hair colour or
aesthetic characteristic. This is
about families being able to
make a decision that their new
baby could save the life of its
older brother or sister,” said
Alison Murdoch, chairman of the
British Fertility Society.
“These are difficult, distressing
and complex real-life situations…
it is important that the views and
interests of the patient are
always put first.”
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Simon Fishel, who runs the
Care fertility clinic at the Park
Hospital in Nottingham said: “I
have no doubt that this is the
right decision.
“The previous stance of not
allowing the selection of an
embryo for tissue typing in our
society was ethically unjustified.
In the real world these families
are often faced with trying to
conceive a tissue-matched child
through natural conception and
this can result in numerous
heart-breaking terminations of
pregnancy, the birth of children
not matched or further children
with a life threatening disease.”
Lord Winston, professor of
fertility studies at Imperial
College, London, dismissed the
designer baby fears. “There
seems little problem for our
society as a whole if a few
families at risk decide to
conceive a baby of a particular
tissue type.”
The debate about whether to
allow selective conception in
particular medical cases began
when an application by Jayson
and Michelle Whitaker, whose
son Charlie had the same
condition as Joshua Fletcher,
was turned down by the HFEA in
2002 on the basis there was no
benefit to the potential baby.
In a 2002 landmark case, the
HFEA agreed that the Hashmi
family from Leeds could use pre-
implantation genetic diagnosis to
create a donor sibling for their
son who suffered from
thalassaemia. But soon
afterwards it ruled that the same
technique could not be used to
help the Whitakers, from
Bicester, whose son, like Joshua
Fletcher, suffers from Diamond
Blackfan anaemia.
It argued that the Hashmi’s
case was different: the primary
reason for screening was to
ensure that the embryo was free
from disease and the tissue
match test was an ‘add-on’. With
the Whitakers there was no
benefit to the embryo, just a
hypothetical risk from the gene
test.
Last month the HFEA said in a
statement that it was now
satisfied there is no increased
risk to the embryo from the
tissue typing test. “The HFEA has
now carefully reviewed the
medical, psychological and
emotional implications for
children and their families as well
as the safety of the technique.
There have been three further
years (since the policy was laid
down in 2001) during which
successful embryo biopsies have
been carried out, both in the UK
and abroad, and we're not aware
of any evidence of increased
risk.”
The HFEA chairwoman, Suzi
Leather, said that research
showed that the babies were not
harmed and that the transplant
risks were low. “Faced with
potential requests from parents
who want to save a sick child,
the emotional focus is
understandably on the child who
is ill,” she said.
But David King, director of the
pressure group Human Genetics
Alert said: “It is wrong to create a
child simply as a means to an
end.”
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